Growth Metrics

Soleno Therapeutics (SLNO) Equity Average (2016 - 2025)

Soleno Therapeutics (SLNO) has disclosed Equity Average for 8 consecutive years, with $472.5 million as the latest value for Q4 2025.

  • For Q4 2025, Equity Average changed N/A year-over-year to $472.5 million; the TTM value through Dec 2025 reached $472.5 million, changed N/A, while the annual FY2019 figure was $22.7 million, 20.74% down from the prior year.
  • Equity Average hit $472.5 million in Q4 2025 for Soleno Therapeutics, up from $367.5 million in the prior quarter.
  • Across five years, Equity Average topped out at $472.5 million in Q4 2025 and bottomed at $140.1 million in Q1 2025.